DermWire | Newest Articles http://practicaldermatology.com/dermwire/ Newest Articles en-us Fri, 23 Feb 2018 01:34:43 GMT Fri, 23 Feb 2018 01:34:43 GMT DermWire Thermi and Sinclair Terminate Collaboration on Silhouette Instalift http://practicaldermatology.com/dermwire/view.asp?url=thermi-and-sinclair-terminate-collaboration-on-silhouette-instalift Thermi, an Almirall S.A. company, and Sinclair Pharma have mutually agreed to terminate their collaboration for the marketing of Silhouette Instalift. Both companies have been working through a joint marketing agreement for two years. Thermi and Sinclair have decided, given the growth opportunities in this market, to focus on their own core business in order to fully leverage its potential. Under terms of the agreement entered into in May 2016, Thermi was granted exclusive four-year distri… Thu, 22 Feb 2018 04:00:00 GMT Vit D Levels Elevated in Acne http://practicaldermatology.com/dermwire/view.asp?url=vit-d-levels-higher-in-acne Levels of vitamin D are higher in acne patients, compared to age/sex matched controls. Researchers found a significant inverse relation between level of 25 hydroxy vitamin D and severity of acne vulgaris before treatment, according to a study in Journal of Cosmetic Dermatology. The study included 90 patients with acne vulgaris and 60 age/sex matched healthy subjects as controls. Patients with acne were treated with 0.75mg/kg/d isotretinoin for three months. Serum level of 25 hydroxy vitamin D… Thu, 22 Feb 2018 04:00:00 GMT MainPointe Pharmaceuticals to Purchase and License Mission’s Consumer Products http://practicaldermatology.com/dermwire/view.asp?url=mainpointe-pharmaceuticals-to-purchase-and-license-missions-consumer-products Mission Pharmacal Company has recently divested several consumer products to MainPointe Pharmaceuticals, LLC. In addition, the marketing rights of additional consumer products have been licensed by Mission to MainPointe. As part of these transactions, the companies have also entered into a renewable Contract Manufacturing Agreement to continue manufacturing all of the included products that are currently made in Mission’s manufacturing facility. These agreements do not involve the marketin… Thu, 22 Feb 2018 04:00:00 GMT ISDIN AGE Contour Launches for Face and Neck http://practicaldermatology.com/dermwire/view.asp?url=isdin-age-contour-launches-for-face-and-neck ISDIN has launched ISDIN AGE Contour, a triple action face and neck cream packed with ingredients to fight three key aspects of skin aging. Formulated with a tripeptide complex containing three key amino acids, AGE Contour is intended to reduce jawline sagging by improving facial firmness, elasticity, and hydration. AGE Contour works to stop advanced glycation end products, or A.G.E.s, which reduce skin suppleness and cause the formation of wrinkles. ISDIN also says the cream protects from… Wed, 21 Feb 2018 04:00:00 GMT New From BrandMD: Advanced Eyelash Growth Serum http://practicaldermatology.com/dermwire/view.asp?url=new-from-brandmd-advanced-eyelash-growth-serum BrandMD's latest product, Advanced Eyelash Growth Serum, is now available. Advanced Eyelash Growth Serum has proven effective within as a little as two weeks of use, the company says. The proprietary formulation features a peptide complex, rich in Biochanin A, to help promote fuller, longer, thicker lashes and reduce the number of lashes lost. Advanced Eyelash Growth Serum is packaged with a brush, safe for the eye area, making it an all-in-one product easy for travel as well. The lash … Wed, 21 Feb 2018 04:00:00 GMT New DermTech Research Validates Gene Expression Against High-Risk DNA Mutations Providing Objective Information for the Diagnosis of Melanoma http://practicaldermatology.com/dermwire/view.asp?url=new-dermtech-research-validates-gene-expression-against-high-risk-dna-mutations-providing-objective-information-for-the-diagnosis-of-melanoma DermTech, Inc. presented a late breaking abstract -- “Validation of Noninvasive Gene Expression (PLA) Against High Risk Driver Mutations (BRAF, NRAS, and TERT) in Cutaneous Melanoma” -- at the 76th Annual Meeting of the American Academy of Dermatology (AAD) in San Diego. The late breaking research by Clay Cockerell, MD, of Cockerell Dermatopathology in Dallas, validated the high performance of the Pigmented Lesion Assay (PLA) against key driver mutations in melanoma. These mutati… Wed, 21 Feb 2018 04:00:00 GMT Asthma and Allergy Foundation Study Shows High Prevalence and QoL Impact for Adults with Atopic Dermatitis http://practicaldermatology.com/dermwire/view.asp?url=asthma-and-allergy-foundation-study-shows-high-prevalence-and-qol-impact-for-adults-with-atopic-dermatitis The Asthma and Allergy Foundation of America (AAFA) shared data demonstrating the high rate of prevalence of atopic dermatitis (AD) in the US adult population and a greater impact on health-related quality of life and mental health symptoms, such as depression and anxiety, for patients with moderate to severe disease compared to those with mild disease. These results are from the Atopic Dermatitis in America Study, an independent research project of the Asthma and Allergy Foundation of America i… Tue, 20 Feb 2018 04:00:00 GMT Dermira Presents Positive Data on Treating Pediatric Patients with Axillary Hyperhidrosis http://practicaldermatology.com/dermwire/view.asp?url=dermira-presents-positive-data-on-treating-pediatric-patients-with-axillary-hyperhidrosis Dermira, Inc. presented new findings from its glycopyrronium tosylate (formerly DRM04) Phase 3 clinical program showing that when applied topically, the investigational therapy improved disease severity, reduced sweat production and was associated with improved quality of life outcomes for pediatric patients (ages 9 to 16) with primary axillary hyperhidrosis (excessive underarm sweating), compared to vehicle-treated patients. These findings, consistent with results previously reported in adul… Sun, 18 Feb 2018 04:00:00 GMT Estée Lauder Companies Anti-Aging Research On Skin Demonstrates Efficacy of Actives and Novel Technologies in Skin Research http://practicaldermatology.com/dermwire/view.asp?url=este-lauder-companies-anti-aging-research-on-skin-demonstrates-efficacy-of-actives-and-novel-technologies-in-skin-research The Estée Lauder Companies Research & Development (R&D) presented research focused on new findings in anti-aging skin research at the 2018 American Academy of Dermatology Annual Meeting in San Diego. The following reserach was presented at poster presentations at the AAD meeting: Anti-Aging Effects of Retinoid Hydroxypinacolone Retinoate on Skin Models Tretinoin, also known as all-trans retinoic acid (ATRA), is well-known for its anti-aging effects on skin; however, issues … Sat, 17 Feb 2018 04:00:00 GMT Ortho Dermatologics Presents Analysis of Siliq Phase 3 Data on Disease-Related Anxiety and Depression in Patients with Psoriasis http://practicaldermatology.com/dermwire/view.asp?url=ortho-dermatologics-presents-analysis-of-siliq-phase-3-data-on-disease-related-anxiety-and-depression-in-patients-with-psoriasis Ortho Dermatologics, a division of Valeant Pharmaceuticals North America, LLC, shared the results from an analysis of the Phase 3 clinical trial AMAGINE-1, which evaluated mental health comorbidities associated with psoriasis, such as anxiety and depression. These findings were presented for the first time at the 76th Annual Meeting of the American Academy of Dermatology (AAD), Feb. 16-20, 2018, in San Diego. “Anxiety and depression occur more frequently among patients with psoriasis t… Fri, 16 Feb 2018 04:00:00 GMT Meet the Newest AAD Officers and Board Members http://practicaldermatology.com/dermwire/view.asp?url=meet-the-newest-aad-officers-and-board-members Suzanne M. Olbricht, MD, FAAD, a Boston-based dermatologist, will take the helm of the American Academy of Dermatology (AAD) as the new President. Her one-year term officially begins on Tuesday, Feb. 20, at the conclusion of the 2018 AAD Annual Meeting in San Diego. Dr. Olbricht is an associate professor of dermatology at Harvard Medical School and chief of dermatology at Beth Israel Deaconess Medical Center in Boston. She previously served the AAD as secretary-treasurer, assistant secretary-… Fri, 16 Feb 2018 04:00:00 GMT Exciplex Phototherapy Device Debuts at AAD 2018 http://practicaldermatology.com/dermwire/view.asp?url=exciplex-phototherapy-device-debuts-at-aad-2018 Excimer Therapies Inc., now has the exclusive U.S. distribution rights for the Clarteis SAS exciplex® phototherapy treatment device. Excimer Therapies officially enters the market and will demonstrate the exciplex during the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California. The event marks the first time the exciplex is available for sale in the U.S. “We are hoping to help dermatologists offer an adjunct or alternative to the current therapies t… Fri, 16 Feb 2018 04:00:00 GMT Some Parents Just Don’t Understand Risks of Indoor Tanning http://practicaldermatology.com/dermwire/view.asp?url=some-parents-just-dont-understand-risks-of-indoor-tanning- Dads, parents who had used indoor tanning devices themselves and those who reported that they had never received skin cancer prevention counseling from their child’s doctor are less likely to believe adolescent indoor tanning is harmful, a new survey shows. To investigate parents’ attitudes toward their children’s tanning behaviors, Maryam Asgari, MD, MPH, FAAD, an associate professor in the department of dermatology at Massachusetts General Hospital and the department of po… Fri, 16 Feb 2018 04:00:00 GMT Merkel Cell Carcinoma Is On The Rise http://practicaldermatology.com/dermwire/view.asp?url=merkel-cell-carcinoma-is-on-the-rise Merkel cell carcinoma (MCC) is on the rise, according to new research published in the Journal of the American Academy of Dermatology and presented at the American Academy of Dermatology 2018 Annual Meeting in San Diego. “MCC is rare, but our research shows that it’s becoming less rare,” says board-certified dermatologist Paul Nghiem, MD, PhD, FAAD, head of the division of dermatology and George F. Odland Endowed Chair in Dermatology at the University of Washington in Seattl… Fri, 16 Feb 2018 04:00:00 GMT Stelara Reduces Aortic Vascular Inflammation http://practicaldermatology.com/dermwire/view.asp?url=stelara-reduces-aortic-vascular-inflammation In addition to its effects on skin inflammation, Stelara (Ustekinumab) reduces aortic inflammation, report researchers from the Perelman School of Medicine at the University of Pennsylvania at the annual meeting of the American Academy of Dermatology in San Diego. Patients who took the drug ustekinumab had a 19 percent improvement in aortic inflammation, as measured and confirmed by imaging, when compared to the placebo group, the study showed. “The type of inflammation we see in pso… Fri, 16 Feb 2018 04:00:00 GMT Biofrontera Rings Nasdaq Market Closing Bell http://practicaldermatology.com/dermwire/view.asp?url=biofrontera-rings-nasdaq-closing-bell Biofrontera AG the specialist for the treatment of sun-induced skin cancer, visited the Nasdaq MarketSite in Times Square. In honor of the occasion, Prof. Hermann Lübbert, PhD, Chief Executive Officer of Biofrontera rang the Closing Bell. Thu, 15 Feb 2018 04:00:00 GMT Restoration Robotics to Showcase ARTAS Robotic Hair Restoration System at Annual AAD Meeting http://practicaldermatology.com/dermwire/view.asp?url=restoration-robotics-to-showcase-artas-robotic-hair-restoration-system-at-annual-aad-meeting Restoration Robotics, Inc. will showcase the ARTAS Robotic Hair Restoration System at The Annual Meeting of the American Academy of Dermatology (AAD) February 15-18 at the San Diego Convention Center in San Diego, CA. At the meeting, Restoration Robotics will host in-booth presentations and discussion sessions with robotic hair restoration experts. These hair restoration experts will review some of the most compelling technical aspects of the ARTAS System and explain why they chose to add the… Thu, 15 Feb 2018 04:00:00 GMT FDA Grants Priority Review for Genentech’s Rituxan for Pemphigus Vulgaris http://practicaldermatology.com/dermwire/view.asp?url=fda-grants-priority-review-for-genentechs-rituxan-for-pemphigus-vulgaris The FDA has accepted Genentech’s Supplemental Biologics License Application (sBLA) and granted Priority Review for the use of Rituxan (rituximab) for the treatment of pemphigus vulgaris (PV). Genentech is a member of the Roche Group. The FDA previously granted Breakthrough Therapy Designation and Orphan Drug Designation to Rituxan for the treatment of PV. Presently, there are limited approved treatment options available for patients with PV. The sBLA submission is based on data from … Thu, 15 Feb 2018 04:00:00 GMT Aqua Pharmaceuticals Supports Camp Discovery http://practicaldermatology.com/dermwire/view.asp?url=aqua-pharmaceuticals-supports-camp-discovery Aqua Pharmaceuticals, LLC is demonstrating its commitment to the dermatology community by supporting American Academy of Dermatology’s Camp Discovery and is making a donation up to $5,000 to support the camp. Camp Discovery is a summer camp designed exclusively for kids undergoing treatment for chronic skin conditions, with five locations throughout the US. Pennsylvania-based Aqua, an Almirall company, is also considering providing employee volunteer opportunities at the in-state c… Thu, 15 Feb 2018 04:00:00 GMT Lilly: New Taltz Data and Pipeline Update to be Presented at AAD Annual Meeting http://practicaldermatology.com/dermwire/view.asp?url=lilly-new-taltz-data-and-pipeline-update-to-be-presented-at-aad-annual-meeting Eli Lilly and Company will present new data for Taltz® (ixekizumab), baricitinib, and mirikizumab at the American Academy of Dermatology (AAD) annual meeting in San Diego. The data include eight abstracts for Taltz, featuring two oral presentations highlighting patient-reported outcomes from a Phase 3 clinical trial evaluating Taltz for the treatment of moderate-to-severe genital psoriasis, as well as findings from the Corrona Psoriasis Registry on Taltz patient clinical characteristics a… Thu, 15 Feb 2018 04:00:00 GMT Zylö Therapeutics: Adam Friedman, MD to Present Data at AAD Annual Meeting http://practicaldermatology.com/dermwire/view.asp?url=zyl-therapeutics-adam-friedman-md-to-present-data-at-aad-annual-meeting Zylö Therapeutics, a nanotechnology-based biopharmaceutical company dedicated to bringing innovative technologies to multiple facets of medicine, announced that preclinical data, utilizing Zylö’s patented hydrogel-derived Nanopods™ to deliver endocannabinoids for the treatment of cutaneous lupus in an established animal model, will be presented for the first time. Dr. Adam Friedman, Associate Professor of Dermatology at the George Washington School of Medicine and Healt… Wed, 14 Feb 2018 04:00:00 GMT NanOlogy Enrolls First Patient in Clinical Trial for Cutaneous Metastases http://practicaldermatology.com/dermwire/view.asp?url=nanology-enrolls-first-patient-in-clinical-trial-for-cutaneous-metastases NanOlogy™, a clinical-stage pharmaceutical development company and affiliate of DFB Pharmaceuticals, has enrolled the first patient in a Phase 1/2 clinical trial of a submicron particle paclitaxel topical anhydrous ointment for the treatment of cutaneous metastases. The open label dose escalating trial of three different strengths of the product will be followed by dose confirmation to evaluate safety. NanOlogy has licensed the topical formulation for use in oncology from DFB Soria, which … Wed, 14 Feb 2018 04:00:00 GMT Lumenis to Introduce PicoFractional Technology at AAD Annual Meeting http://practicaldermatology.com/dermwire/view.asp?url=lumenis-to-introduce-picofractional-technology-at-aad-annual-meeting Lumenis Ltd. plans to unveil the Pico Fractional, a new photoacoustic fractional laser, at the American Academy of Dermatology (AAD) Annual Meeting in San Diego, CA from February 16th-18th, 2018. Pico Fractional, is a new PiQo4 hand-piece, which introduces a fractional laser beam based on photoacoustics. As opposed to traditional laser treatments, which use thermal energy, PicoFractional creates thousands of microscopic treatment zones within the skin, and utilizes the shattering effect of so… Wed, 14 Feb 2018 04:00:00 GMT FDA Accepts Ortho Dermatologics' NDA For Jemdel Plaque Psoriasis Treatment http://practicaldermatology.com/dermwire/view.asp?url=fda-accepts-ortho-dermatologics-filing-for-jemdel-plaque-psoriasis-treatment The FDA has accepted the New Drug Application for Jemdel (halobetasol propionate 0.01%) (IDP-122) lotion from Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. If approved, Jemdel will be the first high-potency topical steroid treatment for plaque psoriasis with dosing for as long as eight weeks. In the clinical trials, the most common adverse event was upper respiratory tract infection. The PDUFA action date is Oct. 5, 2018. "The impact of psoriasis can be d… Wed, 14 Feb 2018 04:00:00 GMT BTL Aesthetics Unveils Body by BTL Campaign http://practicaldermatology.com/dermwire/view.asp?url=btl-aesthetics-unveils-body-by-btl-campaign BTL Aesthetics is celebrating the brand's innovation with a first-of-its-kind campaign for the professional aesthetics industry emphasizing full body results. The Body by BTL campaign showcases the brand's breadth of treatment solutions that are appropriate for everybody, and every body. Aligning the diversified treatment portfolio with a variety of personalities, the campaign chronicles first-hand experiences and life-changing results to inspire consumers to be their most confident self… Tue, 13 Feb 2018 04:00:00 GMT